ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy

Li, Kai; Liao, Ning*; Chen, Bo; Zhang, Guochun; Wang, Yulei; Guo, Liping; Wei, Guangnan; Jia, Minghan; Wen, Lingzhu; Ren, Chongyang; Cao, Li; Mok, Hsiaopei; Li, Cheukfai; Lin, Jiali; Chen, Xiaoqing; Zhang, Zhou; Hou, Ting; Li, Min; Liu, Jing; Balch, Charles M.广东省人民医院; 南方医科大学
Breast Cancer Research and Treatment2020-9DOI: 10.1007/s10549-020-05778-0
4被引6阅读
引用收藏
分享

摘要

Purpose Despite the therapeutic success of existing HER2-targeted therapies, tumors respond quite differently to them. This study aimed at figuring out genetic mutation profile of Chinese HER2-positive patients and investigating predictive factors of neoadjuvant anti-HER2 responses. @@@ Methods We employed two cohorts. The first cohort was comprised of 181 HER2-positive patients treated at Guangdong Provincial People's Hospital from 2012 to 2018. The second cohort included 40 patients from the first cohort who underwent HER2-targeted neoadjuvant chemotherapy. Genetic mutations were characterized using next-generation sequencing. We employed the most commonly used definition of pathological complete response (pCR)-eradication of tumor from both breast and lymph nodes (ypT0/is ypN0). @@@ Results In Chinese HER2-positive breast cancer patients, TP53 (74.6%), CDK12 (64.6%) and PIK3CA (46.4%) have the highest mutation frequencies. In cohort 2, significant differences were found between pCR and non-pCR groups in terms of the initial Ki67 status, TP53 missense mutations, TP53 LOF mutations, PIK3CA mutations and ROS1 mutations (p = 0.028, 0.019, 0.005, 0.013, 0.049, respectively). Furthermore, TP53 LOF mutations and initial Ki67 status (OR 7.086, 95% CI 1.366-36.749,p = 0.020 and OR 6.007, 95% CI 1.120-32.210,p = 0.036, respectively) were found to be predictive of pCR status. @@@ Conclusion TP53 LOF mutations and initial Ki67 status in HER2-positive breast cancer are predictive of pCR status after HER2-targeted NACT.

学科与关键词

关键词
PLUS TRASTUZUMABMOUSE MODELTP53 STATUSOF-FUNCTIONOPEN-LABELP53CHEMOTHERAPYTUMORSMULTICENTERLANDSCAPE
相关
加载中…
  • Heterogeneity of genomic profile in patients with HER2-positive breast cancer
    Bo Chen; Zhang, Guochun; Wei, Guangnan; Wang, Yulei; Guo, Liping; Lin, Jiali; Kai Li; Mok, Hsiaopei; Li Cao; Ren, Chongyang; Wen, Lingzhu; Jia, Minghan; Li, Cheukfai; Ting Hou; Han Han-Zhang; Jing Liu; Balch, Charles M.; Ning Liao*Endocrine-Related Cancer, 2020, 27(3): 153-162.被引 22
  • Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
    Zhang, Guochun; Ren, Chongyang; Li, Cheukfai; Wang, Yulei; Chen, Bo; Wen, Lingzhu; Jia, Minghan; Li, Kai; Mok, Hsiaopei; Cao, Li; Chen, Xiaoqing; Lin, Jiali; Wei, Guangnan; Li, Yingzhi; Zhang, Yuchen; Balch, Charles M.; Liao, Ning*BMC Medicine, 2022, 20(1): 142.被引 47
  • Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations
    Li, Kai; Cao, Li; Li, Cheukfai; Wu, Jundong; Chen, Bo; Zhang, Guochun; Li, Xueri; Wen, Lingzhu; Jia, Minghan; Wei, Guangnan; Lin, Jiali; Li, Yingzi; Zhang, Yuchen; Mok, Hsiaopei; Ren, Chongyang; Wang, Yulei; Qi, Xiaofang; Guo, Lijie; Che, Yue; Liao, Ning*Cancer Medicine, 2023, 12(5): 5195-5208.
查看全部 →

发表信息

论文状态
公开发表
期刊
Breast Cancer Research and Treatment
发表日期
2020-09
卷期
第 183 卷, 第 2 期
页码
321-332
DOI
10.1007/s10549-020-05778-0
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
Guangzhou Municipal Science and Technology Project [201707010418]

作者

  • L

    Li, Kai (第一作者)

    guangdong prov peoples hosp

  • L

    Liao, Ning (通讯)

    guangdong prov peoples hosp · 2 · southern med univ

查看全部 20 位作者收起作者
  • C

    Chen, Bo

    guangdong prov peoples hosp

  • Z

    Zhang, Guochun

    guangdong prov peoples hosp

  • W

    Wang, Yulei

    guangdong prov peoples hosp

  • G

    Guo, Liping

    2 · southern med univ · guangdong prov peoples hosp

  • W

    Wei, Guangnan

    guangdong prov peoples hosp

  • J

    Jia, Minghan

    guangdong prov peoples hosp

  • W

    Wen, Lingzhu

    guangdong prov peoples hosp

  • R

    Ren, Chongyang

    guangdong prov peoples hosp

  • C

    Cao, Li

    guangdong prov peoples hosp

  • M

    Mok, Hsiaopei

    guangdong prov peoples hosp

  • L

    Li, Cheukfai

    guangdong prov peoples hosp

  • L

    Lin, Jiali

    guangdong prov peoples hosp · 2 · southern med univ

  • C

    Chen, Xiaoqing

    guangdong prov peoples hosp · 2 · southern med univ

  • Z

    Zhang, Zhou

  • H

    Hou, Ting

  • L

    Li, Min

  • L

    Liu, Jing

  • B

    Balch, Charles M.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417